Podcasts about Clinical

I'm helping you plan your 2026 growth goals in this episode, whether that's continuing education courses, certifications, clinical skills, or supervision. If you're feeling a little unsure about where to focus next year, this is your chance to reflect, regroup, and set a clear, simple direction for your professional development. I'll walk you through how to identify what actually worked in 2025, choose what's worth your time in 2026, and share a few of my favorite tools that save time and reduce overwhelm - including a note-writing AI I'm loving, and a free CE Course Builder I created just for therapists like you. In this episode, I cover: How to plan CEUs you'll actually enjoy Choosing certifications that align with your goals Building your skills and setting one focus per quarter Tools to streamline your work and free up space to grow Links mentioned in this episode: Browse all the Podcourses Build your first CE course (free)Save time with Berries AI:  get $50 off your first month with code THERAPYSHOW50 Get my Coping with Political Stress Ebook and Peaceful Politics AI Guide  Therapist Conversation Framework: Politics in Session A printable PDF with 97 questions to navigate political talk in therapy - without taking sides. Solution-Focused Therapy Guide72 questions + prompts to help adult clients clarify goals and move forward using SFT. Check out all my Counselor Resources.   

If your therapy techniques only work when you're in the room, that's a problem.Many therapists unintentionally “gatekeep” their expertise and miss opportunities to boost carryover.It's the unexpected downside of being really good at direct clinical work. Don't get me wrong. Clinical judgment does matter. And some things can only be addressed by a trained clinician in a therapy room.But when every decision depends on your personal expertise and physical presence, you've made yourself the bottleneck.In this episode, I'll share how to make the shift towards clear, repeatable systems that others can follow. When you make your methods easier to teach, you make your work scalable, easier to delegate, and far more convincing to leadership.I'll tackle common misconceptions like:✅ “I can't delegate; I don't have direct reports.”✅ “I don't have time for consultation.”✅ “We never get enough time to work on skills.”Plus I share the three steps to making intervention “scalable” so your session plans can start doubling as consultation guides and training tools for others.In this episode, I mentioned Language Therapy Advance Foundations, my program that gives speech pathologists a framework for building language skills needed to thrive in school, social situations, and daily life. You can learn more about the program here: https://drkarenspeech.com/languagetherapyI also mentioned the School of Clinical Leadership, my program that helps related service providers develop scalable executive functioning strategies they can turn into schoolwide initiatives. You can learn more about the program here: https://drkarendudekbrannan.com/clinicalleadership We're thrilled to be sponsored by IXL. IXL's comprehensive teaching and learning platform for math, language arts, science, and social studies is accelerating achievement in 95 of the top 100 U.S. school districts. Loved by teachers and backed by independent research from Johns Hopkins University, IXL can help you do the following and more:Simplify and streamline technologySave teachers' timeReliably meet Tier 1 standardsImprove student performance on state assessments

On the Very Clinical podcast we're suckers for a good story, and our guest, Dr. Dhaval Patel tells one of the best ones we've ever heard!  Kevin and Alan (sorry, no Zach this episode, he's busy mourning the record of his Kansas City Chiefs) welcome Dr. Dhaval Patel to the show. Our plan was to talk about his journey into CAD-CAM dentistry and don't worry, we get there. But he tells the story of how he became a dentist in the US after his training in India and the story is AMAZING. Let's just say that Dhaval has taught us that you need to ask for the things that you want.  Following this amazing story, Dr. Patel recounts his unexpected introduction to CEREC technology in 2006, starting with a dust-collecting Red Cam unit at his Pacific Dental Services office. Despite initial skepticism from colleagues about "shitty crowns," a half-day training session with Dr. Bob Conrad ignited his passion for the technology, leading him to fully embrace it, become an owner-doctor, an early adopter of the Omnicam, a renowned speaker, and the founder of the popular Keep CERECing Facebook group in 2016. He concludes by announcing the upcoming Third Annual Keep CAD Camming meeting in Austin, October 15th-17th, 2026, which will expand beyond CEREC to cover a wider range of CAD/CAM and digital dentistry topics. Some links from the show: Keep CADCAMing Facebook group Dhaval's Instagram Keep CADCAMing website (where you can find information about their upcoming meeting October 15-17th, 2026!) Join the Very Clinical Facebook group!  Join the Very Dental Facebook Group using one of these passwords: Timmerman, Bioclear, Hornbrook, Gary, McWethy, Papa Randy, or Lipscomb!  The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! I'm a big fan of the Bioclear Method! I think you should give it a try and I've got a great offer to help you get on board! Use the exclusive Very Dental Podcast code VERYDENTAL8TON for 15% OFF your total Bioclear purchase, including Core Anterior and Posterior Four day courses, Black Triangle Certification, and all Bioclear products. Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYSHIP" you'll get free shipping on your order! Go save yourself some money and support the show all at the same time! The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!

Today, I'm joined once again by the incredible Dr. Bill Lawrence, a true pioneer in the field of longevity research and one of the most requested guests on this podcast. Dr. Lawrence trained directly with Professor Vladimir Khavinson—the scientist who discovered and developed bioregulator peptides—and has spent the last eight years leading some of the most exciting field research in this space.   Episode Timestamps: Welcome and introduction to Longevity Podcast ... 00:00:00 Origins and early use of bioregulator peptides in Soviet research ... 00:05:39 Organ-specific peptide mechanisms and targeting ... 00:08:28 Dr. Lawrence's collaboration with Professor Cavinson ... 00:12:17 Overview of American clinical studies and study protocols ... 00:14:13 Measuring biological age: telomeres and epigenetic markers ... 00:15:06 Key Russian studies and impact of peptides on mortality ... 00:17:00 Peptides as ultimate epigenetic switches and DNA repair ... 00:20:00 Importance of pineal and thymus peptides in protocols ... 00:22:28 Advances in peptide testing and lab beta-testing ... 00:28:05 Clinical outcomes: organ regeneration and normalized function ...00:35:54 Bioregulator peptides vs. synthetics: modulation vs. boosting ... 00:39:28 Dr. Lawrence's personal telomere and epigenetic age results ... 01:07:56 Impact of stress and meditation on telomere length ... 01:10:37 Group results: significant telomere and epigenetic age reversal ... 01:13:03 System-level organ age tracking and protocol targeting ... 01:27:14 International expansion and next steps in peptide research ... 01:37:03   Our Amazing Sponsors:   Kineon - near-infrared light helps improve circulation, oxygen delivery, and mitochondrial function, which can support focus, recovery, and even overall brain health. Visit kineon.io/NATNIDDAM and get 10% off!   BEAM Minerals - Mineral deficiency support. One shot in the morning, tastes like water, and you've just restored every essential mineral your cells are craving. Go to beamminerals.com, use code NAT20, and get 20% off your first order.   Nootropept by LVLUP - an advanced cognitive enhancement formula that combines fast-acting neuropeptides, cholinergic support, and mitochondrial-boosting compounds to sharpen mental clarity, memory, and long-term brain performance. Visit https://lvluphealth.com/ and use code NAT at checkout for 20% off.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

After 1,000 podcast episodes and over a decade of research, Katie Wells shares her most important discovery: true healing isn't about doing more—it's about simplifying. In this conversation with Dr. Tony Ebel, Katie reveals how she healed from Hashimoto's not through pages of supplements and restrictive protocols, but by prioritizing nervous system health, light exposure, and trusting her body's innate ability to heal. Together, they discuss why the body's electromagnetic nature matters, how stress and complexity prevent healing, and practical (mostly free) strategies for building resilience and adaptability in your family's health journey.-----Links & Resources Access of all Katie's incredible resources here: wellnessmama.comListen to the Wellness Mama Podcast on Apple or your favorite platform!Follow Katie on instagram: @wellnessmama-----Key Topics & Timestamps(00:03:00) - Katie's 1,000th episode milestone and what truly matters after years of research(00:08:00) - Three core principles: body's ability to heal, supplement minimalism, aligning with nature(00:16:00) - The three T's: traumas, toxins, and thoughts—especially the power of inner voice(00:22:00) - Subluxation explained: "a condition less than light" and chiropractic philosophy(00:28:00) - Katie's healing protocol: dropping supplements, no exercise, prioritizing nervous system(00:33:00) - Clinical insight: giving parents permission to stop everything and let healing begin(00:38:00) - Light first: why Katie talks about light before food, supplements, or sleep(00:39:00) - The power of sunrise, sunset, and midday sun exposure(00:42:00) - Electrolytes and minerals: supporting the body's electrical communication(00:49:00) - Movement vs. exercise: gentle movement during healing, not high-intensity workouts(00:53:00) - If you burn easily, you're neuro-inflamed—sun isn't the problem, internal state is(00:59:00) - The banana story: nervous system associations and sensory spillover effect-- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click Here

In this episode of The Clinical Entrepreneur, I walk you through a real case study of a high-stress, high-anxiety patient who turned things around - no labs, no overwhelm, and no complicated protocol.   Instead, I focused on what I call "the low-hanging fruit": stress, sleep, digestion, and diet. You'll hear the exact questions I asked, the protocols I recommended, and the surprising symptom he revealed weeks later.   Want help building clinical confidence like this? Join me inside Clinical Academy  

skinfix began when founder Amy Gordinier discovered a 150-year-old healing balm in a small town in eastern Canada—a shockingly potent formula that outperformed many modern products. The pharmacist's family had boxes of handwritten letters from people whose skin and confidence had been transformed by it. Inspired, Amy rebuilt that legacy with a modern edge, creating skinfix: clean, clinical, barrier-first skincare powered by high-potency actives. The brand is engineered for people who've tried everything and are still searching for real results. skinfix delivers fast-acting repair now and healthier-looking skin over time, tackling stubborn concerns at the root. Their formulas pair clinical actives with moisture-locking hydrators to maximize impact while minimizing irritation. Every product is tested and recommended by unbiased dermatologists and proven to work on real, reactive, complicated skin. If your routine is crowded but your results are lacking, skinfix is the brand built to fix it.In this episode, Amy also discusses:Serving humanity by helping people heal their skin—and, in turn, their livesTackling tough skin issues, from eczema and psoriasis to rosaceaUnlocking glowing skin with the ultimate barrier repair routineThe role of clinical testing: the secret to brand loyalty and credibilityThe importance of cleansing and understanding what your skin truly needsHarnessing the power of organic love on social beyond viral momentsWe hope you enjoy this episode and gain valuable insights into Amy's journey and the growth of skinfix. Don't forget to subscribe to the Glam & Grow podcast for more in-depth conversations with the most incredible brands, founders, and more.Be sure to check out skinfix at www.skinfix.com and on Instagram at @skinfix Rated #1 Best Beauty Business Podcast on FeedPostThis episode is brought to you by WavebreakLeading direct-to-consumer brands hire Wavebreak to turn email marketing into a top revenue driver.Most eCommerce brands don't email right... and it costs them. At Wavebreak, our eCommerce email marketing agency helps qualified brands recapture 7+ figures of lost revenue each year.From abandoned cart emails to Black Friday campaigns, our best-in-class team manage the entire process: strategy, design, copywriting, coding, and testing. All aimed at driving growth, profit, brand recognition, and most importantly, ROI.Curious if Wavebreak is right for you? Reach out at Wavebreak.co

Dr. Greg Hobelmann, Co-CEO/President of Ashley Addiction Treatment alongside Alex Denstman, brings a wealth of experience to his role. Formerly serving as senior vice president and chief clinical/medical officer, Greg now oversees our entire continuum of care including Medical, Clinical, and Spiritual Care, as well as Family Services, Quality Improvement, and Health Information Management. Holding a Master of Public Health from Johns Hopkins Bloomberg School of Public Health, Greg's expertise spans psychiatry, anesthesiology, and pain medicine. With a background in interventional pain management, he focuses on substance use disorders and chronic pain, dedicated to providing innovative holistic care to patients and families at Ashley. Greg currently serves as Secretary on the Executive Committee for the National Association of Addiction Treatment Providers and is Co-Chair of the Public Policy Committee for the Maryland/DC Society of Addiction Medicine. Today on the show we discuss: the complexities of addiction and why the epidemic is so out of control, the nature of addiction and its impact on the brain, strategies for navigating early recovery and regaining control of your life, the ins and outs of the treatment industry and what great treatment actually looks like, what Dr. Hobelmann's latest research suggests about addiction recovery, his advice families and much more. WELLNESS DISCLAIMER  Please be advised; the topics related to health and mental health in my content are for informational, discussion, and entertainment purposes only. The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of your health or mental health professional or other qualified health provider with any questions you may have regarding your current condition. Never disregard professional advice or delay in seeking it because of something you have heard from your favorite creator, on social media, or shared within content you've consumed.If you are in crisis or you think you may have an emergency, call your doctor or 911 immediately. If you do not have a health professional who is able to assist you, use these resources to find help: Emergency Medical Services—911 If the situation is potentially life-threatening, get immediate emergency assistance by calling 911, available 24 hours a day. National Suicide Prevention Lifeline, 1-800-273-TALK (8255) or https://suicidepreventionlifeline.org. SAMHSA addiction and mental health treatment Referral Helpline, 1-877-SAMHSA7 (1-877-726-4727) and https://www.samhsa.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

In the final episode of our five-part series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses bedside testing for PPA.  Show citations:  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

Welcome to the fourth episode of our Early Clinical Learners Series, a series dedicated to fostering clinical reasoning skills and strategies in early clinical trainees. This episode focuses on the musculoskeletal (MSK) block and uses a clinical case to guide listeners through approaching joint pain, identifying key red flags, and narrowing a differential diagnosis.Hosts: Caroline Wang, Samantha Shih, Dr. Richard AbramsGuests: Christopher Song, Grant PrimerProduced By: Caroline Wang, Samantha ShihAlert & Oriented is a medical student-run clinical reasoning podcast dedicated to providing a unique platform for early learners to practice their skills as a team in real time. Through our podcast, we strive to foster a learning environment where medical students can engage with one another, share knowledge, and gain valuable experience in clinical reasoning. We aim to provide a comprehensive and supportive platform for early learners to develop their clinical reasoning skills, build confidence in their craft, and become the best clinicians they can be.Follow the team on Twitter:A&OA fantastic resource, by learners, for learners in Internal Medicine, Family Medicine, Pediatrics, Primary Care, Emergency Medicine, and Hospital Medicine.

Feeling the heavy "grey" of the season? You don't have to force happiness today. Join Martin, your Clinical Hypnotherapist, for a gentle 5-minute morning meditation designed to soothe Seasonal Affective Disorder (SAD) and shift your mood instantly.In this episode, we move beyond toxic positivity and use the science of Polyvagal Theory to introduce you to "Glimmers"—the trending antidote to triggers. While triggers push your nervous system into fight-or-flight, glimmers are micro-moments of safety and connection that anchor you back to calm.In just 5 minutes, you will learn to:Retrain Your Brain: Overcome your mind's natural negativity bias by activating your "Glimmer radar." Soothe Winter Blues: Shift your biology from survival mode into "rest and digest" using somatic regulation. Find Magic in the Mundane: Use visualization to spot micro-joys—like the steam of coffee or a winter robin—to spark instant gratitude. Why listen? If you are struggling with seasonal depression, high-functioning anxiety, or just the weight of the dark months, this session offers a practical tool to help you feel safe, warm, and connected. Become a "hunter of glimmers" and find the light that is already there. Featured Affirmations: "I am open to seeing the magic in the mundane." "Safety and joy are available to me right now." "I choose to focus on what warms my heart."

It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as they hear how feeding Farmatan to bred cows now can help prevent scours this upcoming calving season.  Plus news, markets, updates, bred cow prices and lots more on this all-new episode of The Ranch It Up Radio Show.  Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. How To Prevent Calf Scours: Feed Farmatan   Feed Farmatan To Prevent Scours This Upcoming Calving Season Calving season is getting ready to start for many producers and for some others it is still a ways away yet.  Regardless, we need to get a jump on scours and make sure each and every calf that hits the ground has the best chance of survival.  A simple solution… FARMATAN from Imogene Ingredients.   WHAT CAUSES SCOURS IN BEEF CATTLE/CALVES Clostridia-Enterotoxemia The most common form of Clostridium in cattle is caused by Clostridia perfringens. The gram-positive bacteria are a challenge due to its ability to form spores and lay dormant for long-periods of time. The bacteria reproduce by releasing spores into its environment (soil, feed, manure). The spores can even lay dormant in the animal's intestine until opportunity presents itself. Infection takes place either through ingestion of spores or through an open wound. The most severe cases happen within the first month of a calf's life, and can result in sudden death. Clinical Signs Diarrhea - Bloody, Mucus Present, Bubbly Dehydrated Bloat Blindness Prevention/Treatment: Prevention can be difficult due to the Clostridia spores being extremely durable and present almost everywhere. Complete cleanout and disinfection between calves is helpful, but not always effective. A good vaccination program will reduce clinical disease. The best method is to develop good gut health and the immune system of the calf. Farmatan has been shown to strengthen the intestinal wall, helping to prevent infection from taking hold. Coccidiosis Cattle are host to numerous species of Coccidia, a single-celled protozoal parasite. Infection and clinical symptoms can happen any time during a calf's life, with the most severe reaction usually occurring between 3-6 weeks of age. The life-cycle of coccidia requires time to infect the intestine causing destruction of the mucosal and epithelial lining. The oocytes mature outside the host in warm, moist environments before being consumed, causing infection of a new host. Clinical Signs Diarrhea - Watery, Bloody Depression Weight Loss Prevention/Treatment: Prevention of Coccidiosis is possible by keeping young calves separate from older animals, providing clean water and feed, and dry conditions. Isolation of infected animals is key to preventing transmission. Keeping the pen dry is the most important step a farmer/rancher can take in preventing Coccidiosis. Treatment can have a good impact on reducing secondary disease, and speeding up recovery time. Farmatan has been shown to disrupt the reproductive cycle of Coccidia; and may help strengthen the intestinal wall to prevent infection, in both the cow and calf. Coronavirus Bovine Coronavirus is a ubiquitous, envelope-viral disease, causing respiratory and enteric infection. There are many serotypes for this virus, making it difficult to test for, and create a vaccine. Coronavirus can present as either diarrhea and/or respiratory illness; transmitted through nasal discharge and/or feces. Animal reservoirs continue to spread the disease, and make eradication almost impossible. Clinical disease will likely occur between days 10-14, and present for up to 4 days. Clinical Signs Diarrhea - Watery Nasal Discharge Coughing Prevention/Treatment: Prevention is difficult due to wild animals transmitting the disease. Keeping wild animals out of animal enclosures is essential. Isolation of infected animals is critical to preventing the spread of Coronavirus. Adequate colostrum intake, along with a good vaccination program will help prevent clinical disease. Learn more about the positive effects of Farmtan's active ingredient on Coronavirus HERE. Cryptosporidium Cryptosporidium Parvum is a single-celled parasite responsible for causing infection in young calves. The infection takes place within the first four weeks of a calves' life, afterwards immunity has developed within the calf. The parasite is either passed from the cow or spread through infected water sources. Clinical Signs Diarrhea - Watery, Bloody, Mucus present Colic Depression Prevention/Treatment: Good sanitary conditions, especially clean water is essential in preventing transmission of cryptosporidium. Isolation of sick calves will help reduce the effect on the overall herd. There is some good effect of calves given adequate colostrum, however this is likely helping by reducing other pathogenic loads rather than a direct effect on Cryptosporidium, itself. Farmatan fed prior to calving has been shown to disrupt the life-cycle and reduce transmission from the cow. The direct action of Farmatan on the parasite makes it an excellent choice for treating calves. Learn more about the positive effect of Farmatan's active ingredient HERE. E-Coli Escherichia Coli is a bacterial infection that affects calves within the first week of their life. The bacteria colonize in the lower intestine and produce a toxin. The toxin causes excessive secretion of fluids. The zoonotic disease has special importance in food safety and human health. Colostrum and natural immunity are often not sufficient in preventing infection in cases of high bacterial concentrations. Clinical Signs Diarrhea - Creamy, Yellow Abdominal Pains Fever Vomiting Prevention/Treatment: The best prevention methods for E. Coli include: clean water, dry bedding/environment, isolation of infected animals, and vaccination. Treatment with antibiotics and oral fluids have great benefits in reducing clinical symptoms of the disease. Farmatan has been shown to reduce bacterial load and help prevent infection. Learn more about the positive effects of Farmatan's active ingredient HERE. Rotavirus Rotavirus in calves is caused by a virus belonging to the Reoviridae family, as a non-envelope RNA virus. Rotavirus is thought to be the most common cause of neonatal diarrhea in calves. The virus tends to affect calves between the age of 1-day-old up to a month, with most cases presenting within the first week of life. Shedding and reinfection can happen in older calves and cows. Clinical symptoms are rarely present after the first month of life; older animals tend to either be carriers or asymptomatic. The majority of herds have some level present, with transmission likely happening during or shortly after birth. Clinical Signs Diarrhea - Pale Yellow, Bloody Dehydrated Dull calves Reluctant to drink Prevention/Treatment: The ideal scenario is to prevent infection through, sanitary facilities (calving barn), outdoor calf housing, and a good vaccination program. Colostrum will provide much needed antibodies, protecting the calf before their immune system is fully developed to combat the disease. Farmatan fed prior to calving can help reduce the pathogen load of the cow, reducing the likelihood of transmission. Farmatan supplemented in the milk has been shown to decrease the virus' ability to cause infection and clinical disease. The best treatment for calves already presenting clinical disease is to administer oral fluids/electrolytes to rehydrate the calf. Learn more about the positive effect of Farmatan's active ingredient HERE. Salmonella Salmonella infection of cattle is caused by a variety of species within the family. While the disease is uncommon in cattle with little effect on calf health, it has massive implications for human health and food safety. The bacteria spreads through direct contact or contaminated feed & water. This disease is highly regulated by the USDA. The most severe cases of salmonella affect calves between the ages of 7-10 days old. Clinical Signs Diarrhea - Bloody (flakes of slough tissue), Watery, Mucus present Lethargic Fever Prevention/Treatment: Prevention is always the best option: provide clean water, feed, and bedding. Isolate infected animals, ensure adequate colostrum intake, and develop a vaccination program with your veterinarian. Treatment with antibiotics and fluids (oral or intravenous) greatly increases the survival rate of calves infected with Salmonella. Farmatan has been shown to help reduce the likelihood of infection by protecting the gut, and reduce recovery time of infected animals.  LEARN MORE ABOUT IMOGENE INGREDIENTS  PRODUCTS Paul Mitchell & Paul Martin on RFD TV Rural America Live!  WATCH: https://vimeo.com/759549430/bd063fcc1f Beef Industry News Possible Slow Beef Trend in 2026 According To Rabobank Beef production by major global producers is expected to remain sluggish next year, according to analysts at the Dutch financial services cooperative Rabobank. The recent contraction in beef production is expected to affect major producers in Brazil, Canada and the United States, with New Zealand being likely to see the sharpest percentage drop in beef production, the Rabobank report predicted. Several issues are contributing to the 2025 decline and the expected drop next year, especially in light of limited cattle herds ready for slaughter in both the United States and Brazil, the report added. The long-term contraction of available cattle is being blamed for significant price hikes for retail beef in the last few years, Rabobank noted. Canada is experiencing a tighter pattern that has resulted in a decline of 41,000 metric tons of beef available for export in 2025 versus levels in 2024, according to the report. Canadian beef output in 2026 is expected to be “more limited” compared with this year for reasons also being experienced south of the Canadian border in terms of the available cattle herd. References: https://meatingplace.com/slower-beef-production-trend-to-continue-in-2026-rabobank/?utm_source=omeda&utm_medium=email&utm_cid=1103020073&utm_campaign=MTGMCD251201004&utm_date=20251201-1300 New World Screwworm Website Tracks Parasite There's a new way for producers and other stakeholders to track the fight against the New World Screwworm — a parasite that threatens live cattle herds. The USDA has launched a dedicated website with up-to-date information on the spread of the screwworm, which so far has been confined to cattle in several Mexican states near the U.S. border. The site includes resources for livestock producers, veterinarians, animal-health officials, wildlife experts, healthcare providers, pet owners, researchers, drug manufacturers, and the general public. Reports of the pest in Mexican cattle prompted the U.S. to halt cattle imports from Mexico back in May. USDA also committed $21 million to boost sterile fly production in Mexico as part of its response. The new website pulls together information from multiple federal partners, including the FDA, the Department of Energy, Homeland Security, the EPA, and the State Department.  Reference: https://www.aphis.usda.gov/livestock-poultry-disease/stop-screwworm Nightshade In Corn Residue Could Be Toxic Have you noticed any black nightshade in your corn stalks that you are grazing or plan to graze? If these fields have too much black nightshade, be careful — it might be toxic. Black nightshade is common in many corn fields in the fall, especially those that had hail damage in the summer or any situation where the corn canopy became thin or open. It usually isn't a problem, but if the density of nightshade is very high, there is the potential that it could poison livestock. Almost all livestock, including cattle, sheep, swine, horses and poultry are susceptible.   Black nightshade plants average about two feet in height and have simple alternating leaves. In the fall, berries are green and become black as the plant matures. All plant parts contain some of the toxin and the concentration increases as plants mature, except in the berries. Freezing temperatures will not reduce the toxicity. It is very difficult to determine exactly how much black nightshade is risky. Guidelines say that a cow would need to consume three to four pounds of fresh black nightshade to be at risk of being poisoned. These guidelines, though, are considered conservative since there is little data on the actual toxicity of nightshade plants. Fortunately, even though nightshade plants remain green fairly late into the fall, cattle usually don't appear to seek out nightshade plants to graze. However, green plants of nightshade might become tempting toward the end of a field's grazing period when there is less grain, husks or leaves to consume.  References: https://www.nationalbeefwire.com/nightshade-in-corn-residue-grazing-could-be-toxic Featured Experts in the Cattle Industry Paul Mitchell – Imogene Ingredients https://www.imogeneingredients.com/ Follow on Facebook: @FarmatanUSA Kirk Donsbach – Financial Analyst at StoneX https://www.stonex.com/ Follow on Facebook: @StoneXGroupInc Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: Allied Genetic Resources: https://alliedgeneticresources.com/ American Gelbvieh Association: https://gelbvieh.org/ Axiota Animal Health: https://axiota.com/multimin-campaign-landing-page/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view Medora Boot: https://medoraboot.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Superior Livestock Auctions: https://superiorlivestock.com/ Transova Genetics: https://transova.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/ Wulf Cattle: https://www.wulfcattle.com/

10 Minute Morning Meditation: Instant Calm & Focus | Positive Mindset ResetUnlock your full potential before you even leave your bed.Welcome to a powerful 10-minute morning reset designed to banish morning grogginess and replace it with clarity, confidence, and high-vibration energy. Whether you are waking up with a racing mind or simply want to start your day with intention, this guided practice is your sanctuary.Hosted by Martin, your Clinical Hypnotherapist, this session is perfect for beginners and seasoned meditators alike. We begin by grounding your energy with a visualization of golden light rising from the earth, releasing tension from your jaw and shoulders. You will then invite the warmth of the morning sun to cascade through you, clearing away mental fog and aligning you with your higher self.In this episode, you will:Oxygenate & Unwind: Use deep breathwork to release the residual heaviness of the night.Visualise Success: Seal your intention with the "Golden Light" grounding technique.Reprogram Your Mind: Use powerful affirmations to attract miracles and success effortlessly.Affirmations used in this session: To help these settle into your spirit, we focus on four key pillars of self-belief:"I am ready to rise and shine brighter than ever before.""I am capable of handling this moment.""I choose to focus on my intention today.""I attract miracles and success effortlessly."Make mindfulness part of your daily routine. If you are new here, please subscribe and hit the notification bell to prioritize your peace. Take care, smile often, and be kind.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss the positive side effect of the shingles vaccine on dementia outcomes and how one dose of the HPV vaccine is non-inferior to two doses, but are dismayed about the FDA's secrecy around the inflammatory statement that the COVID-19 vaccine is linked to the death of 10 children. Dr. Griffin then deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, effectiveness of maternal administration of the RVS vaccine or the COVID vaccine for neonates, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how celiac plexus blocks improves gastrointestinal long COVID symptoms, brain alterations and neurodegenerative processes in long COVID cognitive impairment and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode The effect of shingles vaccination at different stages of the dementia disease course (Cell) FDA links 10 children's deaths to COVID-19 vaccines. Doctors want proof (ABC News) Subject: Deaths in children due to COVID-19 vaccines and CBER's path forward Dear Team CBER,(Washington Post) Noninferiority of One HPV Vaccine Dose to Two Doses(NEJM) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Washington state resident believed to be the first to die from a rare strain of bird flu (AP News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Types of Influenza Viruses (CDC: Influenza (flu)) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy (Obstetrics & Gynecology) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Effectiveness of COVID-19 vaccines against post-COVID-19 condition/long COVID: systematic review and meta-analysis (CMI: Clinical Microbiology and Infection) SARS-CoV-2Infection Versus Vaccination During Pregnancy: Implications for Placental Antibody Transfer (The Pediatric Infectious Disease Journal) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Case Report: Celiac plexus block improves gastrointestinal Long COVID symptoms (Frontiers Neuroscience) Distinct brain alterations and neurodegenerative processes in cognitive impairment associated with post-acute sequelae of COVID-19 (Nature Communications) Reaching out to US house representative Letters read on TWiV 1276 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

John Murray, Ali Bruce-Ball & Ian Dennis talk travels, football and commentary. They reflect on a dramatic weekend of Premier League football and look ahead to the weekend's fixtures. John is across the pond for the FIFA World Cup draw. Plus a glut of unintended pub names, heads up for Clash of the Commentators and which commentary phrases will end up in our Great Glossary? Suggestions welcome on WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk00:25 John in Washington DC for World Cup draw 04:50 Dramatic week of Premier League football 09:25 5 Live commentaries this weekend 14:00 Unintended pub names from sport commentary 26:00 Potential twist on the theme? 28:45 Clash of the Commentators 34:50 Great Glossary of Football Commentary5 Live / BBC Sounds Premier League commentaries: Sat 1500 Bournemouth v Chelsea, Sat 1500 Tottenham v Brentford on Sports Extra, Sat 1730 Leeds v Liverpool, Sun 1400 Brighton v West Ham, Sun 1400 Fulham v Crystal Palace.All Clash of the Commentators correct answers: Acheamponh, Alderete, Ballard, Barkley, Bergvall, Beto, Bijol, Bowen, Brobbey, Bruno Guimarães, Calafiori, Calvert-Lewin, Casemiro, Chalobah, De Cuyper, de Ligt, Fernández, Flemming, Foden, Gabriel, Gibbs-White, Gusto, Gyökeres, Haaland, Igor Jesus, Igor Thiago. Isidor, Jiménez, João Pedro, Keane, Kostoulas, Kroupi, Lukic, Maguire, Mateta, Mateus Fernandes, Mayenda, Mbeumo, Merino, Mitoma, Munetsi, Muñoz, Ndoye, Onana, Pedro Neto, Rice, Richarlison, Rodon, Romero, Sarr, Sarr, Schade, Smith Rowe, Thiaw, Timber, Ugochukwu, van de Ven, van Hecke, Welbeck, Wilson, Woltemade, Zubimendi.Glossary so far (in alphabetical order):DIVISION ONE Bosman, Couldn't sort their feet out, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, The Maradona, Off their line, Olimpico, Onion bag, Panenka, Points to the spot, Rabona, Schmeichel-style, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep. DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Catching practice, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Corridor of uncertainty, Easy tap-in, Daisy-cutter, First cab off the rank, Good leave, Half-turn, Has that in his locker, High wide and not very handsome, Hospital pass, Howler, Johnny on the spot, Leading the line, Nutmeg, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Screamer, Seats on the plane, Show across the bows, Slide-rule pass, Steal a march, Stramash, Taking one for the team, That's great… (football), Thunderous strike, Walk it in. UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

In this Thoracic Surgery episode of Behind the Knife we enjoy a conversation with world-renowned thoracic surgeon and educator, Dr. Stephen Yang, as he takes us through 30 years of experience divulging his personal tips, tricks, and pitfalls to avoid when tackling the technical nuances of mastering robotic segmentectomies. Hosts:  Dr. Stephen C. Yang, MD -  professor of surgery and medical oncology The Johns Hopkins Hospital Dr. Kyla D. Rakoczy, MD - PGY3 General Surgery Resident at The Johns Hopkins Hospital Learning Objectives: Understand the utility of segmentectomies for peripheral T1N0 non-small-cell-lung cancer  How to prepare for robotic segmentectomy using CT scans and 3D reconstructions  Learn where to place your ports and how to optimize intra-operative techniques to minimize complications after robotic segmentectomy  References: Kang MW. Evolution of Lung Cancer Surgery: Historical Milestones, Current Strategy, and Future Innovations. J Chest Surg. 2025 May 5;58(3):79-84. doi: 10.5090/jcs.25.025. Epub 2025 Apr 15. PMID: 40230346; PMCID: PMC12066400. https://pubmed.ncbi.nlm.nih.gov/40230346/ Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3. doi: 10.1016/0003-4975(95)00537-u. PMID: 7677489. https://pubmed.ncbi.nlm.nih.gov/7677489/ Pastorino U, Valente M, Bedini V, Infante M, Tavecchio L, Ravasi G. Limited resection for Stage I lung cancer. Eur J Surg Oncol. 1991 Feb;17(1):42-6. PMID: 1995356. https://pubmed.ncbi.nlm.nih.gov/1995356/ Liu L, Aokage K, Chen C, Chen C, Chen L, Kim YH, Lee CY, Liu C, Liu CC, Nishio W, Suzuki K, Tan L, Tseng YL, Yotsukura M, Watanabe SI. Asia expert consensus on segmentectomy in non-small cell lung cancer: A modified Delphi study. JTCVS Open. 2023 Apr 7;14:483-501. doi: 10.1016/j.xjon.2023.03.013. PMID: 37425437; PMCID: PMC10328970. https://pubmed.ncbi.nlm.nih.gov/37425437/ Galvez C, Bolufer S, Lirio F, Recuero JL, Córcoles JM, Socci L, Cabañero A, López I, Sánchez D, Figueroa S, Salcedo JG, Campo-Cañaveral JL, Genovés M, Hernando F, Moldes M, Blanco A, Azcarate L, Rivo E, Viti A, Mongil R. "Complex segmentectomies: Comparison with simple and effect of experience on postoperative outcomes". Eur J Surg Oncol. 2025 Jul;51(7):109748. doi: 10.1016/j.ejso.2025.109748. Epub 2025 Mar 5. PMID: 40064065. https://pubmed.ncbi.nlm.nih.gov/40064065/ Perroni G, Veronesi G. Robotic segmentectomy: indication and technique. J Thorac Dis. 2020 Jun;12(6):3404-3410. doi: 10.21037/jtd.2020.02.53. PMID: 32642266; PMCID: PMC7330783. https://pubmed.ncbi.nlm.nih.gov/32642266/ Montagne, F., Dhainaut, C., & Benhamed, L. M. (n.d.). Pre-operative 3D reconstruction—let's first anticipate the surgical procedure. Video-Assisted Thoracic Surgery. Retrieved November 13, 2025, from https://vats.amegroups.org/article/view/7889/html Shimizu K, Nakazawa S, Nagashima T, Kuwano H, Mogi A. 3D-CT anatomy for VATS segmentectomy. J Vis Surg. 2017 Jul 1;3:88. doi: 10.21037/jovs.2017.05.10. PMID: 29078650; PMCID: PMC5637987. https://pubmed.ncbi.nlm.nih.gov/29078650/ Zhang O, Alzul R, Carelli M, Melfi F, Tian D, Cao C. Complications of Robotic Video-Assisted Thoracoscopic Surgery Compared to Open Thoracotomy for Resectable Non-Small Cell Lung Cancer. J Pers Med. 2022 Aug 12;12(8):1311. doi: 10.3390/jpm12081311. PMID: 36013260; PMCID: PMC9410342. https://pubmed.ncbi.nlm.nih.gov/36013260/ Lee BE, Altorki N. Sub-Lobar Resection: The New Standard of Care for Early-Stage Lung Cancer. Cancers (Basel). 2023 May 25;15(11):2914. doi: 10.3390/cancers15112914. PMID: 37296877; PMCID: PMC10251869. https://pubmed.ncbi.nlm.nih.gov/37296877/ Zhang Y, Liu S, Han Y, Xiang J, Cerfolio RJ, Li H. Robotic Anatomical Segmentectomy: An Analysis of the Learning Curve. Ann Thorac Surg. 2019 May;107(5):1515-1522. doi: 10.1016/j.athoracsur.2018.11.041. Epub 2018 Dec 19. PMID: 30578780. https://pubmed.ncbi.nlm.nih.gov/30578780/ Peeters M, Jansen Y, Daemen JHT, van Roozendaal LM, De Leyn P, Hulsewé KWE, Vissers YLJ, de Loos ER. The use of intravenous indocyanine green in minimally invasive segmental lung resections: a systematic review. Transl Lung Cancer Res. 2024 Mar 29;13(3):612-622. doi: 10.21037/tlcr-23-807. Epub 2024 Mar 27. PMID: 38601441; PMCID: PMC11002498. https://pubmed.ncbi.nlm.nih.gov/38601441/ Altorki N, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Stinchcombe TE. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 2024 Jan;167(1):338-347.e1. doi: 10.1016/j.jtcvs.2023.07.008. Epub 2023 Jul 18. Erratum in: J Thorac Cardiovasc Surg. 2025 Apr;169(4):1181. doi: 10.1016/j.jtcvs.2024.12.011. PMID: 37473998; PMCID: PMC10794519. https://pubmed.ncbi.nlm.nih.gov/37473998/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

The Bulletproof Dental Podcast Episode 417 HOSTS: Kyle Bergman and Colin Ambler GUEST: Dr. Peter Boulden DESCRIPTION In this episode of The Extraction podcast, Dr. Peter Bolden shares his insights on dental practice growth, focusing on staff engagement, effective systems, and the transition from clinical work to business management. He emphasizes the importance of clarity in career goals, the need for robust systems in practice management, and the value of gamification in team engagement. Dr. Bolden also discusses the significance of delegation and finding one's zone of genius to achieve a successful dental practice. TAKEAWAYS Dr. Peter Bolden emphasizes the importance of staff engagement in practice growth. Identifying the right dental model is crucial for success in a new city. Transitioning from clinical work to business requires effective systems. Clarity in career goals can prevent a 'lost decade' in dentistry. Systems should be dynamic and regularly updated to avoid chaos. Gamification can enhance team engagement and accountability. Delegation is key to freeing up time for business development. Understanding your zone of genius helps in effective delegation. Revenue growth can facilitate the transition away from clinical work. Regular audits of daily activities can help identify bottlenecks. CHAPTERS 00:00 Introduction to Dental Practice Growth 02:25 Starting a Dental Practice in a New City 06:50 Transitioning from Clinical to Business 10:31 Building Effective Systems in Dentistry 20:22 Gamification and Team Engagement in Dental Practices 21:16 Hygiene Reactivation Strategies and Metrics REFERENCES Bulletproof Summit Bulletproof Mastermind  

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

In this episode, Matthew W. Johnson, PhD returns to discuss how psychedelics can be leveraged to catalyze human agency. Dr. Johnson has been at the forefront of psychedelic research for 21 years, having conducted seminal research on the effects of psilocybin on mystical experience, personality, and treatment of cancer distress, major depressive disorder, and tobacco addiction. His work with tobacco addiction received the first federal funding for a classic psychedelic in the modern era of research. In this conversation, Dr. Johnson explores psychedelics as powerful enhancers of human agency—the felt capacity to steer one's own life, make meaningful choices, and act from a place of inner autonomy. Drawing from two decades of research across depression, cancer distress, addiction, and healthy volunteer studies, he argues that increases in agency may be a core, yet under-recognized, mechanism behind therapeutic change. Dr. Johnson discusses agency as a "meta-executive" function intertwined with free will, mental flexibility, and meaning-making, and suggests that psychedelics may uniquely illuminate and strengthen this capacity. In closing, he shares thoughts on how individuals can better take advantage of psychedelic-induced neuroplasticity to increase agency in their own lives.   In this episode, you'll hear: What Dr. Johnson means by "agency" and why he sees it as central to psychedelic healing Clinical examples of participants who rediscovered autonomy, changed behaviors, or reframed their suffering after psilocybin sessions Why psychedelics may enhance big-picture psychological flexibility, not just moment-to-moment cognitive flexibility How increased agency may help people with depression, addiction, and cancer distress shift entrenched patterns of thinking and behavior Potential future research directions for studying the neuroscience of agency   Quotes: "It's not just that enhancing agency is the elephant in the room of why psychedelics are working, it's also that I think psychedelics can be a tool for finally understanding this thing of human agency." [4:31] "Even if you think the sense of free will is an illusion, it has to be an evolutionarily advantageous illusion. Why else would it be seemingly universal?" [12:30] "When someone really has one of these 'ah-ha' experiences, they can really come to this perspective of 'no, no, no, no, no, I really am choosing how I'm thinking about myself.' In cancer [patients] it happened a lot." [21:51]   Links: Previous episode: The Latest Research on Psilocybin for Depression with Matthew Johnson, PhD Previous episode: Exploring DMT Entities with Matthew Johnson, PhD Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD Dr. Johnson on X Dr. Johnson on InstagramDr. Johnson on LinkedIn Psychedelic Medicine Association Porangui

Varisha Parikh discusses managing patient expectations in a world that often demands perfection. She breaks down the pressures clinicians face, why honest communication matters, and how setting realistic expectations can lead to better long-term outcomes. With a candid, patient-focused approach, Dr. Parikh shares strategies for helping patients understand the realities of dental work while keeping their well-being at the center of every decision.

Published Dec. 4, 2025In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and the first reported death from alpha-gal syndrome. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories' chief digital innovation officer and medical director of BioPharma Diagnostics, to explore how biopharma diagnostics advance research and development. PAMA reform update (00:33): Get the latest on where reform to PAMA stands following the federal government's reopening.Alpha-gal syndrome case (03:22): Learn about the first known death from alpha-gal syndrome and diagnostic testing for this tick-bite-triggered red meat allergy.Biopharma's role in research and development (07:52): Discover how biopharma diagnostics fuel innovation and how digital tools are expanding its future impact.  Note: Information in this post was accurate at the time of its posting.ResourcesBioPharma Diagnostics: Connecting pharma and biotechTick-borne disease: An expanding geographic threat

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

Dr. Sarah Clarke, DC, IFMCP, and Dave Hogsed, DOM, AP,  discuss traditional and cultural trends around the consumption of organ meats, and the nutritional value these foods offer. They cover nutrients found various organ meats and how they can either be eaten or taken in supplement form. Dave shares clinical success stories, including his own personal experience, using organ meat glandular therapy. He explains how various organ and glandular meats can support immune function, cardiovascular health, nervous system health, cognitive function, bone health, and more. David Hogsed, DOM, AP, is in full time practice at the Natural Healthcare Professionals clinic in Fort Myers, Florida. His practice specializes in providing effective nutritional support for endocrine, digestion, musculoskeletal, nervous system, and immune system health. David has been a clinical consultant and speaker for Standard Process since 2003. His seminars are best known for simplifying clinical nutrition, herbal medicine, laboratory tests, and patient education. David has taught post-graduate programs through Texas Chiropractic College, Logan Chiropractic College, the University of Miami-Miller School of Medicine, Palmer Chiropractic College, Life University, and Northwestern Chiropractic College. He is a regular speaker for the Florida Chiropractic Association, and Palmer Chiropractic College homecoming. SHOW SUMMARY 2:40 Dave's first personal success story with organ meat glandular therapy 5:15 Clinical results from combining organ meat supplements with herbal and nutritional support 7:06 Organ Meats: the forgotten superfoods – historical consumption around the world 8:50 Traditional Chinese Medicine – consumption of organ would support that organ 9:48 Liver: the most nutrient dense organ meat 12:04 Returning popularity of other traditional foods – raw sauerkraut, bone broths, cod liver oil, and more 12:46 Foods essential for health – "you must take it (as a supplement) or eat it" 14:00 Tips for incorporating liver into your diet 15:03 Key benefits of bone broth and bone extracts 16:53 Animals instinctively know the health benefits of organ meats 18:06 The consumption of heart for cardiovascular health 21:30 Combating the effects of stress with organ meats: liver and adrenal glandular extract 23:30 Studies are now finding additional nutritional benefits in organ meats – mRNA 24:21 Nutritional difference between skeletal muscle meat vs. organ meat 27:24 Studies and historical evidence of health benefits of organ meats 28:17 Liver: the ultimate multivitamin 31:00 Organ meats for immune support – thymus extract 32:40 Historical consumption of brain around the world for cognitive health 34:49 Testicular and ovarian extracts for hormone regulation 35:40 The importance of thymus extracts in young children and with aging populations 36:46 Liver is the king of organ meats

Send us a textIn this episode, Dr. Andrew Beverstock discusses his research on urinary sodium and its relationship with growth in preterm neonates. He shares insights into the importance of sodium for neonatal growth, the methodology of his study, and the unexpected results that challenge existing literature. The conversation also touches on his diverse medical training, mentorship experiences, and his involvement in medical education and point-of-care ultrasound (POCUS). Dr. Beverstock emphasizes the significance of careful population selection in research and outlines his future research directions. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode of Healthy Mind, Healthy Life, host Sana sits down with psychotherapist, lecturer, writer, and former British Army soldier Liam Wakefield to unpack what really sits behind the phrase adversity builds character. This is a straight talking deep dive into childhood adversity, war, chronic illness, identity fracture, PTSD language, and the messy inner work it takes to rebuild a self that feels honest. Liam breaks down adversity driven growth, the role of narrative, inner parts, surrender, isolation, and depth without glamorizing suffering.  About the Guest: Liam Wakefield is a psychotherapist, lecturer, and writer who previously spent 11 years as a British Army soldier. His life has moved through childhood adversity, dangerous deployments, a rare genetic condition, and a full career pivot into psychotherapy. He now runs clinical practices in Sussex and London, lectures on depth psychology and trauma, and writes about adversity driven growth, identity, and the internal architecture of the self. Key Takeaways : Adversity is inevitable suffering, not a virtue. It becomes a catalyst for growth only when we change our relationship to the wound instead of forcing quick positivity. The psyche often fractures under pressure. We build defensive structures to survive. Growth starts when we consciously meet those fractured parts instead of pretending to be “fine”. Surrender is different from giving up. Liam describes surrender as accepting that the current version of you cannot carry everything. That honest collapse creates space for a more aligned self to emerge. Identity is made of many parts. Soldier, carer, sick, strong, protector, vulnerable. Healing means learning which part is speaking, which part is in fear, and which part is capable of leading with integrity. Adversity can distort when it becomes your whole identity or a shield from accountability. It deepens character when it is integrated, not worshipped. Real growth is privilege coded to a degree. Community, resources, and psychological support matter. At the same time, isolation and disconnection are often bigger threats than the pain itself. The work is not to be grateful for suffering. The work is to use what happened as data, depth, and perspective without letting it define your future. Connect with the Guest: Listeners can connect with Liam Wakefield here: Website: https://www.liamjwakefield.com/  Social media: Instagram  | Facebook Search for “Liam J Wakefield” on your preferred platform to find his professional updates, writing, and talks on adversity driven growth, psychotherapy, and identity.  Clinical work: Liam runs clinical practices in Sussex and London and also lectures. Details and contact options are available through his website. How to Connect? Be a Guest on Healthy Mind, Healthy Life: Want to be a guest on Healthy Mind, Healthy Life? DM on PM. Send me a message on PodMatch DM Me Here. https://www.podmatch.com/hostdetailpreview/avik Disclaimer This video is for educational and informational purposes only. The views expressed are the personal opinions of the guest and do not reflect the views of the host or Healthy Mind By Avik™️. We do not intend to harm, defame, or discredit any person, organization, brand, product, country, or profession mentioned. All third party media used remain the property of their respective owners and are used under fair use for informational purposes. By watching, you acknowledge and accept this disclaimer. About Healthy Mind By Avik™️ Healthy Mind By Avik™️ is a global platform redefining mental health as a necessity, not a luxury. Born during the pandemic, it has become a sanctuary for healing, growth, and mindful living. Hosted by Avik Chakraborty. storyteller, survivor, wellness advocate. this channel shares powerful podcasts and grounded conversations on. Mental Health and Emotional Well being Mindfulness and Spiritual Growth Holistic Healing and Conscious Living Trauma Recovery and Self Empowerment With over 4,400+ episodes and 168.4K+ global listeners, we unite voices, break stigma, and build a world where every story matters. Subscribe and be part of this healing journey. Contact Brand. Healthy Mind By Avik™ Email. www.healthymindbyavik.com Based in. India and USA Open to collaborations, guest appearances, coaching, and strategic partnerships. Let's connect to create a ripple effect of positive impact. Check Podcast Shows and Be a Guest Listen to our 17 Podcast Shows here. https://www.podbean.com/podcast-network/healthymindbyavik Be a guest on our other shows. https://www.healthymindbyavik.com/beaguest Video Testimonial. https://www.healthymindbyavik.com/testimonials Join Our Guest and Listener Community. https://nas.io/healthymind Subscribe To Newsletter. https://healthymindbyavik.substack.com/ Our Services Business Podcast Management. https://ourofferings.healthymindbyavik.com/corporatepodcasting/ Individual Podcast Management. https://ourofferings.healthymindbyavik.com/Podcasting/ Share Your Story With World. https://ourofferings.healthymindbyavik.com/shareyourstory Stay Tuned and Follow Us Medium. https://medium.com/@contentbyavik YouTube. https://www.youtube.com/@healthymindbyavik Instagram. https://www.instagram.com/healthyminds.pod/ Facebook. https://www.facebook.com/podcast.healthymind Linkedin Page. https://www.linkedin.com/company/healthymindbyavik LinkedIn. https://www.linkedin.com/in/avikchakrabortypodcaster/ Twitter. https://twitter.com/podhealthclub Pinterest. https://www.pinterest.com/Avikpodhealth/ Share Your Review Share your Google Review. https://www.podpage.com/bizblend/reviews/new/ Share a video testimonial and it will be displayed on our website. https://famewall.healthymindbyavik.com/ Because every story matters and yours could be the one that lights the way. #podmatch #healthymind #healthymindbyavik #wellness #HealthyMindByAvik #MentalHealthAwareness #comedypodcast #truecrimepodcast #historypodcast, #startupspodcast #podcasthost #podcasttips, #podcaststudio #podcastseries #podcastformentalhealth #podcastforentrepreneurs, #podcastformoms #femalepodcasters, #podcastcommunity #podcastgoals #podcastrecommendations #bestpodcast, #podcastlovers, #podcastersofinstagram #newpodcastalert #podcast #podcasting #podcastlife #podcasts #spotifypodcast #applepodcasts #podbean #podcastcommunity #podcastgoals #bestpodcast #podcastlovers #podcasthost #podcastseries #podcastforspeakers #StorytellingAsMedicine #PodcastLife #PersonalDevelopment #ConsciousLiving #GrowthMindset #MindfulnessMatters #VoicesOfUnity #InspirationDaily #podcast #podcasting #podcaster #podcastlife #podcastlove #podcastshow #podcastcommunity #newpodcast #podcastaddict #podcasthost #podcastepisode #podcastinglife #podrecommendation #wellnesspodcast #healthpodcast #mentalhealthpodcast #wellbeing #selfcare #mentalhealth #mindfulness #healthandwellness #wellnessjourney #mentalhealthmatters #mentalhealthawareness #healthandwellnesspodcast #fyp #foryou #foryoupage #viral #trending #tiktok #tiktokviral #explore #trendingvideo #youtube #motivation #inspiration #positivity #mindset #selflove #success

In the final episode of our five-part series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses bedside testing for PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

In November 2022, hospitals across Australia began seeing patients with sudden rigidity, spasms, seizures—and in some cases cardiac arrest—after drinking homemade poppy seed tea. The source? Food-shelf poppy seeds contaminated with extraordinarily high levels of thebaine, an opioid alkaloid that acts nothing like morphine. In this Outbreak episode, host Ryan Feldman, clinical toxicologist and emergency medicine pharmacist, investigates how pharmaceutical-grade, thebaine-rich poppy seeds were mistakenly repackaged into the food supply—and how poison centers, clinicians, labs, and public health teams traced and contained the threat within days.You'll hear firsthand from the experts who responded:Dr. Katherine Isoardi, Emergency Physician, Clinical Toxicologist, Medical Director, Queensland Poisons Information CentreDr. Amanda Holford, Clinical Toxicology Fellow & Emergency Physician, Princess Alexandra HospitalDr. Darren Roberts, Medical Director, NSW Poisons Information Centre; Nephrologist; Clinical PharmacologistTogether, they walk us through the outbreak timeline—from the first ICU cases and puzzling “strych­nine-like” neuroexcitation to the multi-state investigation, product recall, and lessons for future foodborne poisonings.Looking for timestamps?A fully timestamped version—so you can jump to any topic—is available to our supporting members.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QBS865. CME/AAPA credit will be available until November 9, 2026.Building Clinical Confidence in the Diagnosis and Multidisciplinary Management of Rett Syndrome In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QBS865. CME/AAPA credit will be available until November 9, 2026.Building Clinical Confidence in the Diagnosis and Multidisciplinary Management of Rett Syndrome In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.Disclosure information is available at the beginning of the video presentation.

In this Dental Leaders episode, Payman sits down with Fabian Farbahi, a 22-year-old Sheffield dental student who's already mastered something most people spend decades learning: the power of genuine conversation. Fabian spends 3.5-hour train journeys striking up chats with strangers because he's fascinated by people's stories—the same curiosity that drove him to become president of Sheffield's dental student society and spend two months on elective in Brazil learning Portuguese. They discuss Fabian's refreshingly unformed career path—he's drawn to oral surgery, intrigued by sports dentistry, passionate about public health behaviour change, and comfortable not knowing exactly which direction he'll take. The conversation covers his transformation from small-town student to confident stage presenter, lessons learned managing volunteers without pay, and why the best time to take business risks is when you're young. What emerges is someone who understands that dentistry isn't just about teeth—it's about connection, communication, and throwing yourself into uncomfortable situations until they become second nature.In This Episode00:03:35 - Choosing Sheffield and moving north00:06:45 - Clinical mistakes and university challenges00:07:40 - Student society presidency00:11:25 - Train conversations and connecting with strangers00:14:20 - Getting into dental school struggles00:17:40 - Career interests: implants, oral surgery, sports dentistry00:20:35 - Public health and behaviour change00:26:15 - Implantology path and the dip00:30:05 - Practice ownership versus travel ambitions00:32:20 - Two-month Brazil elective experience00:41:20 - Six-year projections and taking risks young00:44:30 - Managing people without payment00:50:15 - Business culture and leadership style00:54:50 - FDI World Dental Congress in Istanbul00:58:20 - Shadowing at Evo Dental01:01:30 - Sponsor hunting and sales lessons01:06:00 - Finding confidence through reinvention01:08:50 - Fantasy dinner partyAbout Fabian FarbahiFabian Farbahi is a fourth-year Sheffield dental student who served as president of the Sheffield University Dental Student Society. Originally from Taunton, he recently completed a two-month elective in Brazil, working across multiple cities whilst learning Portuguese and immersing himself in the culture.

In this throwback episode of the Very Clinical Podcast, hosts Zach and Kevin are joined by Dr. Nate Lawson to dive into the evolving world of 3D printing in dentistry. They touch on a variety of topics including the current state of 3D printed crowns, bonding protocols, practical applications in night guards and dentures, and market trends. They also discuss the economic and technological benefits and challenges of integrating 3D printing in a dental practice.  Some links from the show: Wendy's on Twitter The Qualified Captain on Instagram Kevin's Facebook dentinaltube Instagram Join the Very Clinical Facebook group!  Join the Very Dental Facebook Group using one of these passwords: Timmerman, Bioclear, Hornbrook, Gary, McWethy, Papa Randy, or Lipscomb!  The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! I'm a big fan of the Bioclear Method! I think you should give it a try and I've got a great offer to help you get on board! Use the exclusive Very Dental Podcast code VERYDENTAL8TON for 15% OFF your total Bioclear purchase, including Core Anterior and Posterior Four day courses, Black Triangle Certification, and all Bioclear products. Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYSHIP" you'll get free shipping on your order! Go save yourself some money and support the show all at the same time! The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!

In the fourth installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses semantic variant PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

Today's guest is Mathew Paruthickal, Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi. Founded in 1973, Sanofi is a French multinational pharmaceutical and healthcare company. Sanofi works in the research, development, and manufacturing of pharmaceuticals and vaccines. Mathew joins Emerj Editorial Director Matthew DeMello to explore how life sciences organisations can move from isolated digital tools to orchestrated, interoperable systems and how engineering teams can bake in traceability, auditability, and human-in-the-loop governance from day one. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

 KEY TAKEAWAYSHospice isn't a crisis response—it's a planned, values-based care transition.Patients are guided into hospice through ongoing conversations with their care team, not sudden decisions.Your Health's model is uniquely team-based.Clinical teams—NPs, nurses, social workers, CHWs, SSAs—collaborate long before a hospice referral happens.Eligibility is defined by Medicare, but the experience is defined by the patient.Patients choose what services they want: chaplaincy, volunteers, home aides, social work, and moreFamily support is a major part of the program.Hospice helps families avoid panic, emergency room visits, and uncertainty by educating them and offering 24/7 resources.Non-clinical roles are essential.Volunteers, chaplains, and social workers play major roles in emotional, logistical, and spiritual support.Respite care is a game-changer for caregiver burnout.Five-day facility stays covered under the hospice benefit help families regroup, rest, and sustain caregiving.Your Health provides continuity “from pediatrics to end of life.”The organization's ecosystem lets patients receive personalized care at every stage of their life journey. www.YourHealth.Org

Doug Bain, founder and consulting partner of ClinFlo, discusses his proposed regulatory blueprint for digital trials in the latest episode of The Scope of Things podcast. With host Deborah Borfitz, Bain delves into his strategy for turning 21 CFR Part 11 into a more practical regulation that streamlines rather than bogs down clinical trials, what would qualify someone to take on the role as a trusted third party (and what makes them trustworthy), and the new FDA administration's modernization plan aligns—or squares—with his ideas. Plus, the latest news on a tool for detecting fraud and sampling bias in decentralized trials, technology for identifying potentially dangerous drugs before trials start, a novel women's health and menopause initiative, a regenerative therapy for spinal cord injury, and a new oral treatment for preventing dementia. Show Notes :  News Roundup Data collection tools for decentralized trials MyTrials platform study in the Journal of Clinical and Translational Science  Real-time data integration tool Press release on the Mount Sinai website Drug toxicity prediction Article in EbioMedicine  Tufts Women's Health and Menopause Initiative News from Tufts University  Regenerative therapy for spinal cord injury Article in Nature Oral treatment for preventing dementia Press release from Aarhus University  Guest Doug Bain, founder and consulting partner of UK-based ClinFlo  The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology."  "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Listen to the podcast here

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology."  "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Download the transcript here

Does soot in the airway always mean an immediate intubation? Join our Burn Team as they debunk common myths surrounding inhalation injury and distinguish true airway threats from superficial flash burns. We break down critical management strategies, from the 'HAM' protocol to ventilator management, and explain why these patients require massive fluid resuscitation. Tune in to master these high-stakes clinical decisions and ensure you are ready for your next burn patient. Hosts: - Kathleen Romanowski – University of California Davis Hospital, Shriners Hospital Sacramento - Laura Johnson – Grady Memorial Hospital - Lauren Nosanov – Grady Memorial Hospital - Victoria Miles – Louisiana State University Health Science Center, University Medical Center New Orleans Learning Objectives: - Recognize the clinical features and diagnostic challenges of inhalation injury in burn patients, including differentiation from thermal airway injury and flash burns. - Apply evidence-based criteria to guide intubation and ventilatory management, including the avoidance of unnecessary intubation. - Implement key principles of supportive care and complication prevention, including fluid resuscitation, pharmacologic therapies, and long-term airway considerations. References: - Hope E Werenski, Anju Saraswat, James H Holmes, John K Bailey, Is Burn Center Admission Necessary After Home Oxygen Ignition Injury?, Journal of Burn Care & Research, 2025;, iraf189, https://doi.org/10.1093/jbcr/iraf189 - Kathleen S. Romanowski, Tina L. Palmieri, Soman Sen, David G. Greenhalgh, More Than One Third of Intubations in Patients Transferred to Burn Centers are Unnecessary: Proposed Guidelines for Appropriate Intubation of the Burn Patient, Journal of Burn Care & Research, Volume 37, Issue 5, September-October 2016, Pages e409–e414, https://doi.org/10.1097/BCR.0000000000000288 https://pubmed.ncbi.nlm.nih.gov/26284640/ - Walker PF, Buehner MF, Wood LA, Boyer NL, Driscoll IR, Lundy JB, Cancio LC, Chung KK. Diagnosis and management of inhalation injury: an updated review. Crit Care. 2015 Oct 28;19:351. doi: 10.1186/s13054-015-1077-4. PMID: 26507130; PMCID: PMC4624587. https://pubmed.ncbi.nlm.nih.gov/26507130/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

It can often feel in our society, especially for stepmoms, like we have to live in our masculine energy in order to survive. Clinical psychologist Dr. Amanda Hanson wants to dispel that myth.  We'll talk about the importance of embracing your feminine energy, finding the courage to surrender within your relationships, tangible steps you can take to cultivate deeper self love, and the importance of getting curious when you're feeling triggered.  Connect with Dr. Hanson:  Instagram @midlife.muse www.amandahanson.com Get The Disengaging Without Disconnecting Masterclass www.jamiescrimgeour.com/disengaging  Work With Me. www.jamiescrimgeour.com/coaching  Get My Ebook -  120 Ways To Be A KICK-ASS Stepmom www.jamiescrimgeour.com/ebook  Episode Sponsors:  LMNT | My Go To Electrolyte Drink. Head to www.drinklmnt.com/kickassstepmom to get a free sample pack with any drink mix purchase. Cozy Earth | Go to www.cozyearth.com and use the code COZYJAMIE for 20% off of your order

In the third installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses nonfluent/agrammatic PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676  Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506 

Your new hire shadows for a few days. You walk them through a checklist. They learn the software. Then what? Everyone hopes they “figure it out.” A month later, the doctor is frustrated. The team is stressed. The new hire feels like they’re failing. The problem isn’t effort. The problem is this: you’re treating training like a checkbox instead of a culture. Why One Time Training Kills Growth When training is an event, your practice stays stuck in reaction mode. You only coach after mistakes, complaints, or resignations. By then, you’re cleaning up fires instead of building people. Here’s the pattern that plays out in most practices. A new hire gets paired with your “strongest” team member. That leader is already buried in their own workload, so they show shortcuts instead of deep explanations. The new person picks up just enough to stay afloat. Everyone assumes the job is done. But orthodontic practices don’t stay still. Systems change. Software updates. Patient expectations rise. Insurance rules shift. If your team never gets space and structure for continuous learning, they’ll keep doing what they’ve always done. Even when you need something completely different. The emotional toll is real too. Without clear expectations for days 30, 60, and 90, a new hire never knows if they’re winning. They catch feedback only when something breaks. They sense the doctor’s frustration but not the reason. That builds anxiety fast. High performers burn out because they’re constantly training others on the fly. Low performers coast because nobody defined what success actually looks like. Patient experience becomes a coin flip. One family gets a red carpet welcome. The next one gets a rushed check-in from someone who can’t answer basic questions. That’s how training problems quietly become culture problems. Then turnover problems. Then growth hits a ceiling. The Shift — Training As Intentional Culture Flip the switch with one decision. Training isn’t something you check off. It’s something you build into how your practice breathes every single day. Stop playing defense. Start playing offense. Instead of coaching around fires, set a rhythm. Define what someone should know and do at 30, 60, and 90 days. Block time for one on ones, coaching, and questions. Make it clear that learning isn’t just for new hires. It’s for everyone, all the time. This doesn’t require a massive time commitment. Everyone has the same hours in a day. The difference is what leaders choose to prioritize. A 15-minute check-in each week with a key team member can prevent dozens of hours of upset patients, staff gossip, and repeated mistakes. When training becomes your culture, you stop expecting people to just know. You start expecting them to grow. Design Training For Real Humans Here’s another trap. The assumption that everyone learns the same way. Shadowing is valuable. It’s not enough on its own. Some people need hands-on practice with guidance. Others need to talk it through and ask questions. Others need written steps they can review later. When training is generic and rushed, it drains both trainer and trainee. Neither one walks into the next session excited. Mix observation with hands-on work. Break complex processes into smaller wins and celebrate progress along the way. Make room for questions and curiosity, not just lectures. Draw a parallel to continuing education for doctors. Clinicians don’t take one course early in their career and call it done. They keep learning because standards of care change. Your team needs the same commitment. Front Desk staff, Clinical Assistants, and Treatment Coordinators need ongoing growth to stay aligned with what patients expect today, not five years ago. When your entire team is engaged in learning, the practice feels alive. People aren’t just clocking in. They’re getting better. One Role, One Story, Real Transformation Redefining a single role can transform both a person and your whole practice. Picture this. A Front Desk team member has been parked in a corner with an unspoken message: just sit there, answer phones, check people in. Her title reflects it. Her daily experience reflects it. Over time, she internalized the message and operated at that level. Instead of replacing her, reframe the role. Change her title to something like “Patient Satisfaction Specialist” or “First Impression Expert.” Train her on how to stand and greet, how to introduce herself by name, how to guide families through your lobby, and how to create warm, personal phone calls. The shift was immediate. She owned the lobby experience. Patients got greeted with eye contact and genuine care. New callers heard enthusiasm. The Front Desk stopped being a transactional checkpoint. It became a hospitality station that set the tone for everything else. Better greetings and more thoughtful calls helped with retention and reviews. Clinical teams faced less friction because patients already felt cared for before sitting in the chair. Every role in your practice can be a growth lever if you define its purpose and train to that purpose. When people understand the why behind their tasks, accountability stops feeling like punishment. It becomes a badge of pride. Watch how this plays out in daily moments. A team member notices a parent looks cold and offers a blanket without being asked. An assistant remembers a song a patient mentioned and queues it up next visit. A coordinator recognizes a nervous family and slows down to address their real fears. These aren’t random kindnesses. They’re the natural outcome of people who understand their role in the patient journey and feel empowered to act. The Cadence That Works You don’t need a complex training program to make this happen. You need something structured and simple. The heartbeat of this is one on ones. Team huddles matter. Staff meetings are valuable. But nothing replaces looking someone in the eye and talking directly about their experience, their goals, and their growth. Schedule a 15-minute weekly check-in. Ask what’s going well, where they’re struggling, and what support they need. Because this rhythm stays consistent, those conversations feel safe. They signal investment, not trouble. Add a 30-minute monthly development conversation. Review what happened over the past few weeks. Connect performance to specific behaviors and decisions. Talk through real cases, what worked, what could shift next time. Let them use you as a sounding board to brainstorm. Step into a 60-minute quarterly growth conversation. Widen the lens. Discuss personal goals, where they want to grow, and how that connects to where the practice is heading. Treat these as pivot points, moments to reset focus and clarify the next cycle. Start every meeting with what’s working. Make team members feel seen and valued before you talk about gaps. That shift alone primes the conversation for openness and kills the fear that a one on one means they’re “in trouble.” Over time, your team will look forward to these meetings because they feel like real investment. Your 90-Day Action Plan You don’t need to be perfect to start. You need consistency. First, audit how training actually happens right now. Where do new hires get information? Who do they shadow? When do you check-in after week one or two? Where do issues usually surface, front desk or clinic or consultations? Don’t judge. Just observe. The goal is to see the gap between what you intend and what your team actually experiences. Second, pick one role. Maybe it’s the Front Desk. Maybe it’s a Clinical Assistant or Treatment Coordinator. Pick the area where confusion or turnover has been most obvious. For that role, write down what you expect someone to know and do at 30, 60, and 90 days. Keep it simple and rooted in reality, communication, patient experience, and key responsibilities. Third, put a cadence on the calendar. Schedule a 15 minute weekly check-in and a 30-minute monthly conversation for the next three months. Decide right now that you’ll start each meeting by asking what’s going well. That one habit changes the tone more than anything else. Listen closely during those conversations. Where does this person feel unclear, undervalued, or underused? What part of their role do they love? Where do they feel least confident? Invite them to share ideas for improving patient experience or efficiency in their area. Then empower them to run one small experiment. Maybe it’s a new greeting script. Maybe it’s a comfort station with blankets and stress toys for anxious families. Maybe it’s better follow-up on pending treatment plans. Define what success looks like together and decide how you’ll measure it. At day 90, step back and compare. How is this person performing now? How has their confidence shifted? What’s the impact on patients or the rest of your team? Use those insights to refine the cadence and roll it out to the next role. The Practice You Build Training problems aren’t solved by one more manual or a longer orientation. They’re solved when training becomes a living part of how your practice operates. When you move from one time training to ongoing coaching, everything shifts. Team members feel valued instead of disposable. Expectations are crystal clear instead of vague. Accountability feels like empowerment instead of punishment. Patients feel the difference the moment they walk through your door. They see it in a genuine greeting. They hear it in a caring voice. They feel it when someone remembers their name or anticipates what they need. As your team grows, your practice grows. Turnover drops. Reviews climb. Your days stop feeling like fire drills and start feeling like purposeful, predictable progress. You don’t need a perfect system. You only need to decide that training is no longer a box to check. Choose one role. Set a simple cadence. Have the conversations. Let continuous coaching become the heartbeat of your culture. Start this week. Free Growth Session The post 10 Training Mistakes Ruining Your Orthodontic Practice appeared first on HIP Creative.

If you've been waiting for a GLP-1 weight loss medication that doesn't require injections, special timing, or refrigeration—this episode is for you. Learn about the groundbreaking oral pill that could hit the market as early as 2026. For years, effective obesity medications have meant needles. But Orforglipron could change everything. In this episode, I break down the science, clinical trial results, and approval timeline for this first-of-its-kind once-daily pill that delivers GLP-1 benefits without the injection barriers. Whether you're needle-averse, struggle with injection site reactions, or simply want more convenient options, this new medication could expand access to life-changing obesity treatment.   Episode Highlights: What makes Orforglipron different from Wegovy, Zepbound, and oral semaglutide Clinical trial results: 12.4% average weight loss over 72 weeks Why this oral pill doesn't require fasting or special timing like other oral GLP-1s The FDA accelerated review process and potential 2026 approval timeline Who benefits most: patients with needle phobia, injection site reactions, or seeking maintenance therapy What to expect regarding insurance coverage and access once approved   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Want to become a Supervisor on your own terms AND pay it forward to future clinicians so they be great and get licensed? Grab my Supervision Guide Starter Pack: ACCESS HEREJOIN THE INHER COLLECTIVEYouTubeInstagram

This episode discusses the current guidelines for the treatment of adult cardiopulmonary arrest, reviews evidence-based algorithms aimed at improving outcomes of survival and discusses the role of pharmacologic therapies recommended for pulseless rhythms.  CE for this episode expires on November 29, 2027.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello wish everyone a Happy Thanksgiving and then decry appointment of the Louisiana State surgeon general as deputy chief of the CDC, the 3 children's deaths during this fall's pertussis outbreak, the Marburg virus outbreak in Ethiopia, results of the phase 1 safety trial for the novel poliovirus vaccines nOPV1 and nOPV3, and the first human death from H5N5 influenza virus infection in the US this fall, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, effectiveness of the cell or egg based flu or the mRNA vaccines, immunogenicity and efficacy of updated COVID-19 vaccines, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, immune and cognitive dysfunction during long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Anti-science Movement: Deputy director of CDC (X:Louisiana Office of the Surgeon General) CDC's new deputy director is vocal critic of vaccines, advocated for ivermectin (CIDRAP) Whooping cough cases on the rise in Texas (FOX4: KDFW) Third infant in Kentucky dies of whooping cough as national cases stay high for second year in a row (CIDRAP) More than 25,000 whooping cough cases reported this year as Kentucky records 3rd infant death (ABC News) Vaccination Coverage and Exemptions among Kindergartners (CDC: SchoolVaxView) Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV‐related disease and harms from vaccination (Cochrane Library) Marburg Outbreak in Ethiopia: Current Situation (CDC: Marburg Virus Disease) Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial (LANCET: Infectious Diseases) Washington state resident believed to be the first to die from a rare strain of bird flu (AP News) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023–2024 Season (Infectious Diseases and Therapy) Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine(NEJM) ACIP Recommendations Summary (CDC: Influenza) Types of Influenza Viruses (CDC: Influenza (flu)) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease (CID) FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication (FDA) Brag Sets Off a Chain Reaction — Dr. Oz Takes the Bait, But Fumbles the Math, and Starts Unraveling Mid-Interview (Atlanta BlackStar) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study (LANCET: Infectious Diseases) Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants (OFID) SARS-CoV-2 vaccination and myositis in Norway and Sweden (Rheumatology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Digitally Assessed Long COVID Symptomatology Is Associated With Lymphocyte Mitochondrial Dysfunction and Altered Immune Potential (OFID) Evaluation of Interventions for Cognitive Symptoms in Long COVID (JAMA Neurology) Reaching out to US house representative Letters read on TWiV 1274 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

DMSO is a proven "umbrella remedy" that treats dozens of "incurable" conditions and protects delicate tissues (especially brain and eyes) from otherwise fatal injuries such as a complete loss of blood flow DMSO has a unique, almost magnetic affinity for the eyes, routinely restoring vision in disorders conventional medicine considers untreatable — including decades-long and lifelong blindness DMSO shields the retina from ischemic strokes, intense light damage (e.g., staring directly at the sun), and progressive degenerative diseases such as retinitis pigmentosa, glaucoma, and many others covered below Clinical studies and dozens of reader reports confirm DMSO halts or reverses macular degeneration — often returning eyesight that patients believed was gone forever. Beyond severe disease, DMSO dramatically improves everyday vision: sharper focus, better contrast and night vision, fewer floaters, and many people reduce or eliminate their need for glasses In extreme but meticulously documented cases — including a man blind from birth for 75 years and others blind for decades after severe trauma — DMSO has rapidly restored functional sight that modern medicine had declared impossible

Ian Dennis returns alongside John Murray & Ali Bruce-Ball to talk travels, football and commentary. Steve Bunce joins the pod with boxing returning to BBC primetime television this weekend for the first time in 20 years. Clash of the Commentators returns. Plus your unintended pub names and the Great Glossary of Football Commentary. Suggestions welcome on WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk01:10 Ali excited about his new purchase 03:40 The In-Form Ian Dennis 05:40 Premier League commentaries this weekend 09:35 Champions League format ‘not right' 14:15 Where is Liverpool's next win coming from? 20:25 Unintended pub names from sport commentary 26:35 Steve Bunce joins the pod to talk boxing 35:35 Clash of the Commentators 42:20 Great Glossary of Football Commentary 49:30 An observation from Jamie and Oliver5 Live / BBC Sounds Premier League commentaries: Sat 1500 Man City v Leeds, Sat 1500 Sunderland v Bournemouth on Sports Extra, Sat 1730 Everton v Newcastle, Sun 1405 West Ham v Liverpool, Sun 1405 Aston Villa v Wolves on Sports Extra, Sun 1405 Nottingham Forest v Brighton on Sports Extra 2, Sun 1630 Chelsea v Arsenal.Glossary so far (in alphabetical order):DIVISION ONE Bosman, Couldn't sort their feet out, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, The Maradona, Olimpico, Onion bag, Panenka, Rabona, Schmeichel-style, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep. DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Catching practice, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Corridor of uncertainty, Easy tap-in, Daisy-cutter, First cab off the rank, Good leave, Half-turn, Has that in his locker, High wide and not very handsome, Hospital pass, Howler, Johnny on the spot, Leading the line, Nutmeg, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Screamer, Seats on the plane, Show across the bows, Stramash, Taking one for the team, That's great… (football), Thunderous strike. UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

In this Huberman Lab Essentials episode, my guest is Dr. David Spiegel, MD, the Associate Chair of Psychiatry & Behavioral Sciences, Director of the Center on Stress and Health, and Director of the Center for Integrative Medicine at Stanford University School of Medicine. We discuss the science and clinical applications of hypnosis, including how hypnosis works in the brain. We examine the evidence-based uses of clinical and self-hypnosis for pain, trauma, phobias, sleep and stress, and explain how to gauge your own level of "hypnotizability." We also outline practical ways to access these tools, from working with a trained clinician to using structured self-hypnosis protocols. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Function: https://functionhealth.com/huberman Rorra: https://rorra.com/huberman Timestamps (00:00:00) David Spiegel (00:00:20) What is Hypnosis?; Clinical vs Stage Hypnosis (00:02:33) Brain & Hypnosis, Cognitive Flexibility (00:06:14) Sponsor: Function (00:07:54) ADHD, Self-Hypnosis & Focus (00:08:57) Stress Reduction, Mind-Brain Connection; Improve Sleep, Phobias (00:12:16) Narrative & Hypnosis, Mental State Change; Reframing Trauma (00:18:26) Sponsor: AGZ by AG1 (00:19:56) Naming Importance; Clinical Hypnotist, Durability of Hypnosis, Reveri App (00:22:29) Obsessive Thoughts, OCD, Hypnosis (00:23:47) Hypnotizability, Spiegel Eye Roll Test, Eye-Brain Connection (00:27:02) Sponsor: Rorra (00:28:31) Trauma Recovery, Deliberate Self-Exposure to Pain or Trauma, Control (00:30:37) Mind-Body Connection, Control; Reframing Pain, Tool: Opportunity for Action (00:33:22) Children & Hypnosis; Group Hypnosis (00:35:09) Breathing in Hypnosis, Cyclic Sighing, Relaxation (00:36:46) Peak Performance & Hypnotic States (00:37:55) Reveri Hypnosis App, Finding Clinical Hypnotist; Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Clinical psychologist Dr. Ramani Durvasula joins Kelly to discuss how to navigate through the world of narcissism and high conflict relationships. Dr. Ramani shares if you need to leave or end relationships with narcissists, how to co-parent with one AND Andy Cohen dials in to ask how to win an argument with a narcissist. Plus, Producer Lisa takes us behind the scenes of BravoCon! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.